Xeris Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +122.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 4.9% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation F
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 48.7x | Better than 8% |
| Price / Sales | 8.3x | Better than 13% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 85.4% | Better than 94% |
| Operating margin | 8.5% | Better than 46% |
| Net margin | 0.2% | Better than 27% |
| Return on equity | -324.2% | Better than 2% |
| Return on invested capital | -17.5% | Better than 14% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 95.1% | Better than 100% |
| 6-month return | 174.2% | Better than 100% |
| 12-month return (ex latest month) | 49.3% | Better than 83% |
| Distance below 52-week high | 1.8% | Better than 98% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.2x | Better than 60% |
| Debt to assets | 67.3% | Better than 6% |
| Interest coverage | 1.0x | Better than 29% |
| Free cash flow / net income | 5,041.5% | Better than 99% |
Analyst View C
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | -2.8% | Better than 2% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 16.62
- Open
- 16.61
- Day range
- 16.53 - 17.04
- Avg price
- 16.82
- Volume
- 2.86M
- Turnover
- 48.05M
- Turnover ratei
- 1.62%
- Volume ratioi
- 1.01
- Amplitudei
- 3.04%
- 52-week rangei
- 5.25 - 17.28
Valuation
- P/Ei
- 5,656.67
- P/E (TTM)i
- -628.52
- P/Bi
- 63.56
- EPSi
- 0.00
- Book value / shi
- 0.27
- Net profit
- 548.10K
- Net assets
- 48.78M
Share structure
- Market cap
- 3.10B
- Float capi
- 3.00B
- Shares out
- 182.70M
- Float sharesi
- 176.52M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-06-21
1.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-37.15M net over the window
Short interest
- Shares short
- 8.99M
- % of floati
- 4.93%
- Days to coveri
- 4.34
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Xeris Pharmaceuticals (XERS)?
Xeris Pharmaceuticals last traded at 16.97. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Xeris Pharmaceuticals's market cap?
About 3.10B.
What is the P/E ratio of Xeris Pharmaceuticals?
The trailing twelve-month P/E is -628.52, below its own 5-year average of 60.12 — toward the bottom of its historical range (0.08% percentile). See the Valuation tab for the full history.
Does Xeris Pharmaceuticals pay a dividend?
Xeris Pharmaceuticals does not currently pay a regular dividend.
Is Xeris Pharmaceuticals a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 16.50, which implies 2.8% downside from the current price. This is not investment advice.
What is Xeris Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Xeris Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.
Xeris Pharmaceuticals discussion 0 comments